CIK 0001798749
- Emerging growth company
Jade Biosciences, Inc.
Sign in to watch- Ticker
- JBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831377888
- Phone
- +1 781-312-3013
- Business address
- 221 CRESCENT ST., BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aerovate Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 84 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-07-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −200 | 13,894 | ||
| 2023-07-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −650 | 42,108 | ||
| 2023-07-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −750 | 50,732 | ||
| 2023-07-03 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 | +10,000 | $2.14 | $21K | 10,000 |
| 2023-07-03 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −10,000 | $18.00 | $180K | 0 |
| 2023-07-03 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 393,381 | ||
| 2023-06-06 | Dake Benjamin T SEE REMARKS | Option exercise 10b5-1 | +2,412 | $1.74 | $4K | 3,703 |
| 2023-06-06 | Dake Benjamin T SEE REMARKS | Option exercise 10b5-1 | +7,871 | $2.14 | $17K | 11,574 |
| 2023-06-06 | Dake Benjamin T SEE REMARKS | Sale 10b5-1 | −10,268 | $16.28 | $167K | 1,306 |
| 2023-06-06 | Dake Benjamin T SEE REMARKS | Sale 10b5-1 | −15 | $16.98 | $255 | 1,291 |
| 2023-06-06 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −905 | 6,339 | ||
| 2023-06-06 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,507 | 21,095 | ||
| 2023-06-06 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,018 | 22,405 | ||
| 2023-06-06 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,853 | 164,461 | ||
| 2023-06-06 | Santel Donald J Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2023-06-06 | Katabi Maha Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2023-06-06 | GRAYZEL DAVID S. Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2023-06-06 | Resnick Joshua Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2023-06-06 | Iwicki Mark T Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2023-06-06 | Dorval Allison Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 |
Page 15 of 16 · 315 trades